Circio invited to present advantages of circVec circular RNA technology at international industry conferences
Oslo, Norway 26 February 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky have been invited to present the circVec platform and benefits of circular RNA at two upcoming biopharma industry conferences in Basel, Switzerland, and Stockholm, Sweden.
The presentations will detail the advantages and potential of circular RNA to improve on current mRNA-based technology for a range of therapeutic applications. Circio’s latest circVec 3.0 generation demonstrates significantly increased and prolonged protein expression, with up to 75 times half-life extension for circRNA compared to conventional linear mRNA in mouse models.
RNA Leaders Europe Congress
Title: Deploying circular RNA expression to boost gene therapy – AAV and beyond
Time & place: 5 March 2025, 11:05 CET, Basel, Switzerland
Presenter: Dr. Erik Digman Wiklund, CEO
Biologics World Nordics 2025
Title: CircVec – A Novel Payload Expression Platform Based on Circular RNA Biogenesis: Features and Opportunities
Time & place: 5 March 2025, 11:35 CET, Stockholm, Sweden
Presenter: Dr. Victor Levitsky, CSO
These invitations to present at important RNA industry conferences highlight Circio´s position as a leader in circRNA placed along other pioneering RNA companies such as Alnylam, CureVac and Sail Biomedicines. It follows the recent invitation by Nature Review Genetics to author a comprehensive review article on the therapeutic potential of synthetic circular RNA and vector-based circular RNA expression.
The presentations will be made available on Circio´s webpage on the respective dates.